Prenatal gene therapy has been considered for Herlitz junctional epidermolysis bullosa (H-JEB), a lethal genodermatosis caused by the absence of any of the three subunits of laminin-5, resulting from birth in widespread blistering and erosions of skin and mucosae. To investigate this strategy in an animal model, adenovirus type 5-and adeno-associated virus (AAV) type 2-derived vectors carrying a b-galactosidase reporter gene or LAMB3 cDNA encoding the b3 chain of laminin-5 were generated, tested for stability in amniotic fluid and evaluated in vitro on murine H-JEB keratinocytes, and in vivo by prenatal injection into the amniotic cavities of laminin-5 b3-deficient mice. The different vectors were administered individually or combined at maximum doses on day 14 post coitum. Adenoviral vectors infected preferentially the foetal epidermis, whereas AAV delivered the transgene mainly to mucous membranes of the airways and the upper digestive tract. The LAMB3 transgene was expressed in target epithelia of newborn laminin-5 b3-deficient mice, and the transgenic b3 chain was shown to assemble with its endogenous partner chains, resulting in detectable amounts of laminin-5 in the basement membranes of skin and mucosae and in a lower extent of tissue separation in the skin. However, only combined delivery of the two vector types led to a minor increase of the life span of H-JEB mice. Failure to rescue diseased animals was, at least in part, due to abandonment of any conspicuous pup by the heterozygous mother. This is the first study of a prenatal gene therapy approach to a heritable blistering disorder. Although our findings indicate that prenatal combined administration of adenoviral and adeno-associated LAMB3 vectors provides therapeutic benefit to H-JEB mice, this animal model appears unsuitable for long-term investigations of the therapeutic concept.
Introduction
Herlitz junctional epidermolysis bullosa (H-JEB) is a rare recessively inherited blistering disease caused by absence of any of the three subunits of the basement membrane protein laminin-5. It presents from birth with widespread blistering and peeling away of the epithelial layer of skin and mucous membranes, which leads to a loss of protein and iron, chronic infection, poor feeding, refractory anaemia and early demise of the patients. Most H-JEB patients suffer incredibly from large confluent wounds and die within the first 2 years of life. At present, there is no specific therapy for H-JEB, and wound treatment is only supportive. 1 We and others have investigated the use of allogeneic skin grafts or artificial skin equivalents to treat the cutaneous manifestations of this disease; 2, 3 however, these approaches were limited by immune responses against the transplanted cells. As the patient's immune system has not encountered laminin-5, ex vivo gene therapy approaches involving genetically corrected autologous epidermal stem cells are likely to be affected by the same problem. We have attempted to overcome the immune barrier in an H-JEB patient by haematopoietic stem cell transplantation and subsequent 80% skin exchange by grafts from the same donor, but despite successful proof of principle we failed to save the life of this child. 4 Gene transfer in utero may be an alternative way to avoid adverse immune responses to an exogenous therapeutic protein.
Recently, we used this approach to induce sustained immune tolerance of transgenic clotting factor 5, 6 and to achieve permanent phenotypic correction of haemophilia B in immunocompetent mice. 7 Prenatal gene delivery provides the best possible access to still expanding stem cell populations that are inaccessible later in life and may thus represent a promising therapeutic strategy for a number of heritable diseases, for which any postnatal treatment may not be delivered in time to avoid irreversible disease manifestation. 8, 9 The feasibility of this concept has been demonstrated in different animal models. 6, [10] [11] [12] [13] [14] [15] [16] Our previous work on ultrasound-guided gene delivery to the sheep foetus 17, 18 has shown that a broad range of foetal somatic cells can be accessed with minimal invasion and trauma.
In H-JEB, involvement of the mucous membranes of trachea and upper digestive tract is frequent, which can result in severe impairment of respiration, feeding and digestion. 1 However, as third-trimester foetuses already perform regular breathing and swallowing movements, not only the whole skin surface but also all relevant internal mucosae may be reached by administration of a corrective vector into the amniotic fluid surrounding the foetus. This, in fact, is still the only approach that raises hope for a real cure of the devastating Herlitz disease.
Laminin-5 is a structural glycoprotein of the lamina lucida reaching down to the lamina densa of the epidermal basement membrane zone. 19 Its interaction with the integrin a6b4 in hemidesmosomes is essential for a stable anchorage of the basal epithelial cells to collagen VII molecules of the underlying connective tissue. 20 The laminin-5 molecule is assembled from three multidomain polypeptide chains, a3, b3 and g2, linked by disulphide bonds to form a cross-shaped structure with the C-terminal regions of the polypeptides constituting the triple-stranded helical coiled coil. 21 Only the assembled heterotrimer is transported selectively from the endoplasmatic reticulum to the Golgi apparatus for glycosylation and subsequently to the cell surface, followed by secretion and proteolytic cleavage. 22 The subunits of laminin-5 are encoded by three distinct genes located on human chromosomes 1 and 18. Most H-JEB patients carry premature termination codons in both alleles of any of these genes. 23, 24 The majority of H-JEB mutations reside in the gene LAMB3.
Adenovirus type 5-and adeno-associated virus (AAV) type 2-based vectors have emerged as efficient vehicles for gene transfer in vivo and shown promise in clinical studies. [25] [26] [27] Although such vectors rarely integrate their transgene into the genome of keratinocytes and other epithelial cells, a prenatal gene transfer strategy with the aim to overcome the most critical neonatal days appeared as a realistic option. As both vector types have been considered to be well suitable for gene transfer into keratinocytes, [28] [29] [30] we decided to investigate their potential for prenatal gene therapy of H-JEB in a mouse model of this disease carrying an intracisternal A particle (IAP) insertion of spontaneous origin in the gene LAMB3. 31 
Results

Characterization of the animal model
Before gene therapy experiments, the mouse model had to be characterized in detail. In 42 litters of heterozygous LAMB3 IAP parents, 26% of the newborn pups were homozygous for the IAP insertion, suggesting that lack of laminin-5 does not compromise embryonic and foetal survival. In contrast to LAMA3-knockout mice, 32 the weight of the newborns was comparable with that of their wild-type littermates. Homozygous LAMB3 IAP mice survived for between 1 and 30 h after birth. These animals showed extremely fragile skin immediately after birth, including ablation and dislodgement of the entire epidermal layer in high-friction areas such as the paws (Figure 1a) , denuded limbs and tail tips and large skin blisters filled with clear fluid (Figure 1b and c) , contributing to rapid dehydration of the body. These features made most of them easily distinguishable from their heterozygous or genetically normal littermates. The additional development of mucosal blisters prevented proper sucking, resulting in poor feeding of diseased pups. As the mothers recognized affected offspring very quickly and abandoned it, 96% of the newborn homozygotes died within 24 h after birth because of dehydration and hypothermia. Genotyping of all animals was performed by a robust polymerase chain reaction (PCR) on tail tip samples obtained after birth (Figure 1d ), replacing the intricate long-range PCR proposed by Kuster et al. 31 Interestingly, sometimes also heterozygous and wildtype offspring was abandoned by the mothers, indicating such abandonment to be an intrinsic post-gestational behaviour of heterozygous LAMB3 IAP mice. Only about 70% of the phenotypically normal mice with at least one normal LAMB3 allele survived the first days. This fact is likely to limit also the maximum survival rate for homozygous mice treated by any therapy.
Suitability of adenoviral and AAV vectors for infection of the target tissues
As gene therapy vectors were to be administered into the amniotic fluid, components of which may inhibit infectivity of the virus, 33, 34 we first tested the stability of reporter gene vectors, AdLacZ and AAVLacZ, in amniotic fluid. In vitro, both vector types were able to infect different human cell lines in the presence of fresh human amniotic fluid (10-100%) with good efficacy, although in pure amniotic fluid the infectivity of the adenoviral vector was slightly reduced, while AAVmediated gene delivery proved to be unaffected (data not shown).
Following vector application in vivo, nuclear targeting b-galactosidase activity was observed in periderm, epidermis and mucous membranes of the oral cavity, oesophagus and trachea of treated animals, but not in parenchymatous organs of these mice. The adenoviral vector infected preferentially the foetal epidermis ( Figure  2a ), whereas AAVLacZ infected murine keratinocytes poorly (data not shown). Both vector types delivered the reporter gene to mucous membranes of the oral cavity and the upper airways, however, adenoviral gene transfer (Figure 2b ) was clearly more efficient than AAV-mediated transduction, for which maximum transgene expression was observed only 8-10 days after the infection (Figure 2c ). Our observations of the unexpected poor efficacy of AAV2 were in agreement with a recent report on intra-amniotic administration of an AAV vector to foetal rabbits, 14 but in contrast to a previous study by Braun-Falco et al., 29 which indicated AAV to be a good candidate for gene transfer into keratinocytes. Nevertheless, because of the different time courses of transgene expression and the basic suitability of AAV2 for prenatal gene delivery to relevant mucosae, which may be most important for the feeding capability of newborn mice, we decided to continue the study with both an adenoviral and an AAV vector.
Functional characterization of LAMB3 vectors
The vectors AdLAMB3 and AAVLAMB3, both carrying the cDNA for the human laminin-5 b3 chain under the control of the cytomegalovirus (CMV) promoter, were Prenatal LAMB3 gene delivery in mouse model of Herlitz disease C Mühle et al generated and characterized functionally by infection assays on different human and murine cell lines and primary keratinocytes. Three days after the infection, the transgenic protein was visualized by immunofluorescence, and a band of the correct size (140 kDa) was detectable in Western blots from lysates of the infected cells (data not shown). As the amino-acid sequences of the human and the murine b3 chain show only 82.5% homology, we had to investigate whether the transgenic human b3 chain could assemble intracellularly with the murine a3 and g2 partner chains to a chimeric heterotrimer that would be secreted like native murine laminin-5. Following infection of JWF2 cells (murine keratinocytes) with AdLAMB3, radiolabelled culture supernatant was immunoprecipitated using an antibody against the human b3 chain, which does not crossreact with murine b3. The precipitation products are shown in Figure 3 . Five components of a chimeric laminin-5 heterotrimer, the subunits a3 (200 kDa), g2 (155 kDa) and b3 (140 kDa) and the processed forms of the a3 chain (165 kDa) and the g2 chain (105 kDa), were detected in the supernatant of AdLAMB3-infected JWF2 cells, but not in that of untreated control cells. As the immunocomplexes contained transgenic human b3 protein, this must have been part of assembled laminin-5 molecules secreted by the murine cells. Furthermore, in AdLAMB3-infected primary keratinocytes from homozygous LAMB3 IAP mice, human b3 protein was detectable by immunofluorescence, both intra-and extracellularly (Figure 4 ). Because the b3 chain cannot be secreted on its own, 22 this extracellular staining was interpreted as additional indirect proof of intracellular assembly with the murine a3 and g2 chains.
Detection of vector DNA and transgene expression in newborn LAMB3 IAP mice following prenatal gene transfer To evaluate the vectors AdLAMB3 and AAVLAMB3 in vivo, experimental groups A, B and C were formed, the animals of which received AdLAMB3, AAVLAMB3 or a combination of both, respectively. In each group, all foetuses of the second pregnancy of heterozygous parents were treated by intra-amniotic administration of 5 Â If genotyping of the complete litter was impossible owing to total cannibalization of any dead pups, the whole litter was excluded from the study.
The foetal survival rates (percentage of animals born after the procedure) were similar in these three groups, ranging from 79 to 84%.
Quantitative PCR was used to study the vector distribution to skin and mucous membranes of the oral cavity. In group A, vector DNA was found in skin and mucosa samples of all animals with maximum copy numbers of 1.1 Â 10 5 /mg tissue and 5 Â 10 4 /mg tissue, respectively. In group B, AAVLAMB3 DNA was detectable only in nine of 12 skin samples at generally much lower levels, but in 11 of 12 mucosa samples from the treated mice. In group C, adenoviral DNA was detected Prenatal LAMB3 gene delivery in mouse model of Herlitz disease C Mühle et al in both skin and mucosa of most animals, whereas AAVLAMB3 DNA was again less frequent in the skin than in mucosa samples (Table 1) . Vector DNA was not found in the livers of prenatally treated mice. In particular, there was no evidence for gene transfer into the gonads.
Tissue samples of treated homozygous animals were further investigated for transgene expression both by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and immunofluorescence staining. Similarly to the results of the vector distribution analysis, LAMB3 mRNA was mainly detectable in the skin of animals of group A and in the mucous membranes of the animals of group B with copy numbers up to 2 Â 10 5 /mg tissue in the skin and even 1 Â 10 6 /mg tissue in the 
Detection of AAVLAMB3 in mucosa
AdLAMB3 only (A; n ¼ 9) 9/9 (100%) 9/9 (100%) Not applicable Not applicable AAVLAMB3 only (B; n ¼ 12)
Not applicable Not applicable 9/12 (75%) 11/12 (92%) AdLAMB3+AAVLAMB3 (C, n ¼ 11)
11/11 (100%) 9/11 (82%) 7/11 (64%) 9/11 (82%)
Prenatal LAMB3 gene delivery in mouse model of Herlitz disease C Mühle et al mucosa samples. Interestingly, a much larger number of LAMB3 transcripts were found in both tissue samples from 10 out of 11 treated homozygous mice of group C ( Figure 5 ). In these animals, the mRNA copy numbers ranged from 2 Â 10 5 to 1.7 Â 10 6 /mg tissue in the skin and from 1.0 Â 10 6 to 5.8 Â 10 6 /mg tissue in the mucous membranes. In skin samples from two animals of group A and seven animals of group C, the transgenic b3 chain was also detectable by immunofluorescence in the epidermal basement membrane zone (Figure 6a) , as indicated by overlay with signals of the basement membrane marker protein nidogen-1 (Figure 6b ), whereas no specific signals were obtained in samples from untreated controls (Figure 6c and d) .
Indications of a therapeutic benefit of LAMB3 gene transfer
In homozygous LAMB3 IAP mice, significant expression of the LAMB3 transgene appeared to be associated with increased survival time. Following combined administration of AdLAMB3 and AAVLAMB3, two animals, C2 and C4, survived for 30 and 26 h, respectively. Two others, C8 and C9, survived for approximately 53 h, which had never been observed for untreated homozygous LAMB3 IAP mice. However, although LAMB3 mRNA had been clearly detectable in skin and mucous membranes from C2, C4, C8 and C9 ( Figure 5 ), there was no clear correlation between amount of transgenic mRNA in the tissue samples and survival time. Unfortunately, even the combined delivery of the two vector types failed to rescue any homozygous LAMB3 IAP mice and led only to a minor increase of the life span in 30% of the treated animals ( Table 2 ). The main reason for that appeared to be the regular abandonment of any conspicuous pup by the mother. To circumvent this problem, two additional groups of prenatally treated newborn animals had been transferred to foster mothers or brought up in a special incubator, which also failed to rescue the homozygous LAMB3 IAP mice. Furthermore, two other groups of mice were treated in utero with higher doses of AdLAMB3 (up to 4 Â 10 10 p.p., corresponding to 3 Â 10 9 i.p.). This, how- Prenatal LAMB3 gene delivery in mouse model of Herlitz disease C Mühle et al ever, resulted in significantly decreased foetal survival rates explainable by the known toxicity of adenoviral vectors, which had been observed at very similar doses also in our previous studies. 11 Although in human H-JEB patients the number of hemidesmosomes is decreased, this parameter could not be used for evaluation of therapeutic effects in our mouse model, because the number of hemidesmosomes in homozygous LAMB3
IAP mice is similar to that in wildtype mice. 31 Therefore, the extent of tissue separation was assessed semiquantitatively in histological sections of skin from the trunk and mucous membranes of the oral cavity (Table 3) . One animal from group A and five animals from group C showed a clearly reduced extent of skin separation in comparison with untreated controls, and in only one of 11 treated homozygous mice of group C more than 40% of the epidermis were detached. In all treatment groups, there was a tendency towards less tissue separation in the mucous membranes (Table 3 ). Figure 7 shows the increased integrity of skin (Figure 7a ) and mucous membranes (Figure 7b ) in one of the mice from group C, which survived for more than 24 h in 
comparison with an untreated control animal (Figure 7c and d). Taken together, the histological results confirmed that the only significant indication of a therapeutic benefit was seen in group C. In summary, we observed independent indications of therapeutic benefit of a combined intra-amniotic administration of AdLAMB3 and AAVLAMB3 to homozygous LAMB3 IAP mice, but were unable to rescue the animals by prenatal gene therapy.
Discussion
This study is the first report on a prenatal gene therapy approach to a fatal inherited blistering disorder. It documents the difficulties of exploring this therapeutic strategy in a particular mouse model.
The first unforeseen problem was encountered in our initial experiments with reporter gene vectors. In contrast to a study of Braun-Falco et al. 29 on human keratinocytes, mouse keratinocytes were only infected poorly by AAV2 vectors. Our results were, however, more in accordance with the recent report of GagnouxPalacios et al. 35 on the suitability of different viral vectors for gene transfer into primary human keratinocytes, which indicated the failure of AAV2 to infect such keratinocytes in vitro, as well as with a study of Boyle et al., 14 who observed no transgene expression in the skin following intra-amniotic delivery of AAV2 vectors to foetal rabbits. This problem is likely to be owing to a particular insufficiency of AAV2 rather than to differences between the animal species. A recent study by Braun-Falco et al., 36 however, has attributed low gene transfer efficacy of AAV2 in keratinocytes to impaired cellular trafficking of the vector particles as well as to high levels of autophosphorylated epidermal growth factor receptor tyrosine kinase and demonstrated increased and persistent transgene expression after treatment of the cells with quinazolines or a proteasome inhibitor. On the other hand, AAV2 infected the epithelial cells of mucous membranes with greater efficacy. Because the development of mucosal blisters in laminin-5-deficient mice can prevent normal feeding of diseased pups, mucosal infection, which was not achieved consistently with adenoviral vectors, may be of particular importance for their survival. Therefore, we decided to test an AAV vector in parallel to an adenoviral vector on LAMB3 IAP mice that lack the b3 chain of laminin-5. We chose day 14 post coitus for the intraamniotic injections as a compromise between the time frame for most efficient infection of basal-layer keratinocytes, including epidermal stem cells and the earliest time point at which foetal breathing and swallowing movements are observed in mice.
AAV2 proved even more stable in amniotic fluid than adenoviral vectors, which fits well with the results of Boyle et al., 33 and dose-limiting vector toxicity was only observed for the adenovirus. Therefore, we assumed that a sufficient number of target cells in skin and mucosae could be reached by intra-amniotic injection of the highest safely applicable or available doses of AdLAMB3 and AAVLAMB3, respectively. In these experiments, the combination of both vector types proved superior to administration of each vector on its own, as indicated by detection of transgenic mRNA and protein, histology and survival time of treated homozygous animals. This synergistic effect was somewhat surprising, although it could be explained, for example, by the known ability of adenoviral vectors to enhance AAV-mediated gene transfer by overcoming a block in the conversion of single-stranded viral genomes into transcriptionally active, double-stranded molecules, which has been attributed to the expression of the adenoviral earlyregion E4 open-reading frame 6. 37 Strongly enhanced AAV transduction efficacy by addition of low amounts of an adenoviral vector was demonstrated previously in a rat model. 38 The in vivo results of our study are in agreement with these data, although higher concentrations of adenovirus were used. Conversely, adenoviral attachment, infection or transgene expression may have been increased by simultaneous application of AAV, either directly via so far unknown mechanisms or indirectly, because a more than 10-fold molar excess of AAV may have neutralized inhibitory substances present in the amniotic fluid. AAV infection, naturally dependent on helper virus co-infection, could also lead to an upregulation of coxsackie and adenovirus receptor as well as a V integrins on the cell surface, which would modulate adenovirus entry. Signalling pathways required for efficient integrin-mediated internalization of adenoviral vectors or their endosomal trafficking may be altered in a cell infected with AAV. The efficacy of AAV-mediated gene transfer can rise upon exposure of infected cells to genotoxic or physical stress, which is assumed to be associated with an induction of the host cell DNA repair machinery. 37 Likewise, the combined administration of AAV and adenoviral vectors may lead to a higher transcriptional activity as a response to increased stress. Further investigations using combinations of active and inactivated AAV and adenoviral vectors are required to distinguish between enhancement of AAV-and adenovirus-mediated transgene expression and to elucidate the mechanisms responsible for the apparent synergistic effect.
Furthermore, a combination of adenoviral and AAV vectors may provide the advantages of complementary tropisms of the different vector types or short-term highefficacy transgene expression from the adenovirus and longer lasting transgene expression from the AAV. Moreover, in a clinical setting even a relatively low level of transgene expression may suffice to induce immune tolerance of transgenic laminin-5 and allow additional postnatal treatment with gene therapy vectors without the risk of immune rejection of the corrected cells.
A major disadvantage of the mouse model used was the problem of regular maternal neglect of all conspicuous progeny. The mice appear to recognize affected pups very rapidly, abandon them typically within a few hours after birth and later cannibalize the dehydrated bodies. Sometimes even phenotypically healthy heterozygous and wild-type offspring was affected by abandonment. Thus, reducing the number of their pups appears to be an intrinsic post-gestational behaviour of this mouse strain. In our experimental settings, obviously any phenotypic changes resulting from prenatal gene transfer were insufficient to protect affected newborns from such abandonment by their mothers. Our attempt to bring homozygous pups up in a special incubator by hand-feeding unfortunately did not improve the situation significantly, because the newborn Prenatal LAMB3 gene delivery in mouse model of Herlitz disease C Mühle et al mice did not show sufficient weight gain independent of their genotype and died within 2 days. The failure of homozygous pups to thrive cannot be attributed to problems of breathing or food digestion, because in contrast to a6b4 integrin-null mice the LAMB3 IAP mice were shown to be free of blisters in tissues of the lower respiratory, urinary or gastrointestinal tract. 31 Rapid inactivation of the CMV promoter in mouse tissues is also not likely to be the reason for the failed rescue, because we have shown CMV-driven expression of other transgenes, for example, human clotting factor IX cDNA, for many months after prenatal administration of an adenoviral vector. 6 Thus, we assume that in this H-JEB model, despite using the strong CMV promoter, neither the amount of transgenic laminin-5 provided by our gene therapy vectors nor the time frame for achievement of maximum transgene expression could meet demands for the rescue of homozygous LAMB3 IAP mice. The described post-gestational behaviour of the LAMB3 IAP mouse mothers is, of course, very different from the human situation, where the required particular care would be provided for a diseased baby and most H-JEB patients survive the neonatal period. Furthermore, in human patients, the amount of transgene expression necessary for significant clinical improvement may be much lower than in LAMB3 IAP mice, because these animals carry a large insertion disrupting the gene LAMB3, whereas in human H-JEB patients, the disease is mostly caused by single-nucleotide changes, for which somatic reversions leading to mosaicism have been reported. 39 Thus, despite the independent indications from this study that prenatal combined administration of adenoviral and AAV vectors carrying LAMB3 cDNA may offer therapeutic benefit, the LAMB3 IAP mouse model of H-JEB appears only appropriate to short-term evaluation but unsuitable for long-term investigations of a gene therapy approach. This may, unfortunately, also apply to the other available mouse models of H-JEB, which were created by targeted disruption of the genes LAMA3 or LAMC2. 32, 40 Nevertheless, any new therapy that may provide at least short-term benefit allowing homozygous foetuses to overcome the first critical days should be evaluated in one of these mouse models.
An inducible mouse model similar to that described by Arin et al. 41 for dominantly inherited epidermolysis bullosa simplex may offer better possibilities to evaluate therapeutic effects at different stages of the disease; however, for H-JEB, an inducible mouse model is not yet available. Alternatively, gene therapy can be investigated in vivo on keratinocytes from human H-JEB patients or laminin-5-deficient mice following transplantation onto severe-combined immunodeficient mice, similarly as in a recently published approach to the treatment of recessive dystrophic epidermolysis bullosa. 42 This, however, does not allow evaluation of any prenatal gene therapy attempt with its advantages of inducing immune tolerance of the transgenic protein 6 and providing access to the relevant mucosae -as an option for families, in which the disease is diagnosed prenatally.
For long-term studies, other animal models of H-JEB such as dogs or horses 43 may be used. Sustained phenotypic correction of canine keratinocytes with a spontaneous mutation of the gene LAMA3 has recently been achieved by oncoretroviral gene transfer. 44 Oncoretroviruses, however, are less stable in amniotic fluid 34 and bear a greater risk of insertional mutagenesis. Therefore, novel vector systems such as adenovirus/ AAV hybrid vectors allowing site-specific integration of the transgene into the host genome 45 may be more promising for prenatal gene therapy of H-JEB.
Despite the limited success of our prenatal gene therapy attempt in LAMB3 IAP mice, this novel approach to treatment of H-JEB deserves further exploration using optimized vectors in other animal models.
Materials and methods
Vectors
The replication-deficient adenovirus type 5 vector AdLAMB3 containing full-length cDNA for the human laminin-5 b3 chain under the control of the CMV promoter was generated by homologous recombination using the shuttle plasmid pVQAd5CMV-K-NpA. Viral particles were produced by ViraQuest (North Liberty, Iowa, USA).
The AAV serotype 2-derived vector AAVLAMB3 was created by inserting the human laminin-5 b3 chain cDNA driven by a minimal CMV promoter into an AAV2 backbone provided by Genethon III (Evry, France). The virus was produced in human embryo kidney 293 cells by co-transfection of three plasmids as described by Xiao et al. 46 in a helper virus-free system. AAV concentrations in the purified vector preparation were determined by dot blot and photometric assays according to the established procedures. 47 The vectors AdLacZ and AAVLacZ containing a bacterial b-galactosidase reporter gene were prepared as described previously.
5,11
Primary keratinocyte culture Primary laminin-5-deficient mouse keratinocytes were isolated from skin samples from the back of newborn homozygous LAMB3 IAP mice as described by Meng et al., 40 transferred into six-well plates which had been coated with human type IV collagen (100 ng/ml; SigmaAldrich, Seelze, Germany) and cultured in keratinocyte growth medium (PromoCell, Heidelberg, Germany), including recombinant human epidermal growth factor (0.125 ng/ml), bovine pituitary extract (0.4%; vol/vol), hydrocortisone (0.33 mg/ml), human transferrin (10 mg/ ml), human insulin (5 mg/ml), epinephrine (0.4 mg/ml) and CaCl 2 (0.15 mM), supplemented with 5% foetal calf serum (FCS) and penicillin/streptomycin (100 U/ml). The laminin-5-deficient cells adhered to the coated wells and were grown at 371C and 5% CO 2 for 1 week.
Infection assays in vitro
The stability of adenoviral and AAV vectors in amniotic fluid was assessed in infection assays on the human cell lines HT1080 (fibrosarcoma; American Type Culture Collection (ATCC): CCL-121) and HepG2 (hepatocellular carcinoma; ATCC: HB-8065), which were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS and penicillin/streptomycin (100 U/ml). The cells were infected at a density of 1 Â 10 5 cells/well in 24-well plates. Following washing with phosphate-buffered saline (PBS), 5 Â 10 6 i.p. of
AdLacZ or AAVLacZ in fresh human amniotic fluid (sterile remnants from elective amniocentesis samples), DMEM or DMEM containing 10% fresh human amniotic fluid were added to the wells and replaced by complete culture medium 3 h later. After 48 h of incubation at 371C, transgenic b-galactosidase activity was determined in cell lysates using chlorophenol red galactopyranoside (1 mg/ml; Roche, Mannheim, Germany) as substrate in PBS, pH 8.0, containing MgSO 4 (1 mM), KCl (10 mM), b-mercaptoethanol (50 mM) and bovine serum albumin (BSA) (0.1%), in parallel to a standard curve of b-Dgalactoside galactohydrolase (Sigma-Aldrich, Seelze, Germany). Colour development was quantified after 4 h by measuring the absorbance at 580 nm. Functionality of AdLAMB3 and AAVLAMB3 was tested in vitro on keratinocytes from homozygous LAMB3 IAP mice. The bases of single wells of a 24-well plate (TPP, Trasadingen, Switzerland) were excised, sterilised and coated with human type IV collagen as described above. Primary laminin-5-deficient keratinocytes were harvested when subconfluent, seeded at a density of 1 Â 10 5 cells/well onto the type IV collagencoated 24-well base, which was placed in a six-well plate, and cultured in complete keratinocyte growth medium for 36 h before infection. Following careful washing, the cells were infected with 4 Â 10 7 i.p. of the respective vector in serum-free culture medium, which was replaced by complete keratinocyte growth medium after 1 h. Two days later, the cells were investigated by immunofluorescence analysis.
Radioimmunoprecipitation
JWF2 cells (murine keratinocytes; obtained from Dr Susan Fischer, MD Anderson Cancer Center, Houston, TX, USA) cultured in DMEM containing 10% FCS and penicillin/streptomycin (100 U/ml) were infected with AdLAMB3 30 h before radiolabelling. Untreated JWF2 and HaCaT cells (human keratinocytes) served as controls. Labelling was performed by replacing the culture medium with methionine/cysteine-deficient minimal essential medium (Sigma-Aldrich, Seelze, Germany) supplemented with 10% FCS, sodium pyruvate (1 mM), b-mercaptoethanol (2 mM) and 100 mCi of 35 S-methionine (MP Biomedicals, Heidelberg, Germany). Following 24 h of incubation at 371C, radiolabelled conditioned medium was collected, cleared of cellular debris, pre-cleared with protein G sepharose beads (GE Healthcare, Munich, Germany) and used for immunoprecipitation with the monoclonal antibody K140, 48 which recognizes the human laminin b3 chain, but does not crossreact with murine b3. Immunoprecipitation was performed overnight at 41C under agitation. Then protein G sepharose beads were added to capture the antibody-protein complexes, washed four times with radioimmunoprecipitation buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.05% Triton X-100, 0.4% Nonidet P40, 0.3% sodium deoxycholate, 0.1% BSA and protease inhibitors), resuspended in a reducing loading buffer and denatured. Proteins were separated on a 6% denaturing sodium dodecyl sulphate (SDS)-polyacrylamide gel and visualized using a PhosphoImager system (Fuji, Kanagaba, Japan). 9 and 4 Â 10 1 p.p. Prenatal injections were performed at day 14 post coitum. The pregnant animal was anaesthetized by intramuscular injection of 1 ml/g body weight of a 1:2 (vol/vol) mixture of xylazine (20 mg/ml; Bayer, Kiel, Germany) and ketamine hydrochloride (100 mg/ml; Wyeth, Wurselen, Germany) or by isoflurane inhalation. Following midline laparotomy, the uterus horns were consecutively pulled out of the abdomen until exposed completely, and 40 ml of the vector suspension were injected through the intact uterus wall into the amniotic cavity of each foetus using Hamilton 250 ml syringes with needles of 33 G (Hamilton, Bonaduz, Switzerland). After suturing the maternal abdomen in two stages by interrupted stitches, the animal was permitted to recover in a pre-warmed cage and to give birth normally. Newborn mice were left with their mothers and observed closely during the first 3 days of life. In two additional experimental groups, the newborn animals were either given to foster mothers or brought up in a special incubator providing constant air temperature of 35.51C and a relative humidity of 80%, where they were fed every second hour with partially adapted soya milk using a pipette with a 20 ml tip.
All procedures on animals were conducted in accordance with the German and British Home Office Regulations and Legal Requirements.
Genotyping
Tissue samples from living animals were obtained by tail clipping. Genomic DNA was extracted by incubation with proteinase K (0.4 mg/ml final concentration) in tail lysis buffer (50 mM Tris, pH 8.0, 50 mM KCl, 2.5 mM EDTA, 0.45% Nonidet P40, 0.45% Tween 20) overnight at 561C. After vigorous vortexing and subsequent pelleting of the cell debris by centrifugation, the supernatant was diluted 1:50 and used for genotyping by multiplex PCR in a reaction mixture containing the primers The PCR products were analysed by gel electrophoresis on a 1.0% agarose gel. In wild-type mice, PCR resulted in a single fragment of 670 bp (see above). If the IAP insertion of 5.3 kb was present, the multiplex amplification led to a dominant product of 1119 bp instead, whereas the theoretically obtainable second fragment of 6 kb was undetectable under the PCR conditions described.
X-gal histochemistry
Whole newborn mouse bodies were divided sagittally and fixed in a 2% formaldehyde/0.2% glutaraldehyde solution, washed three times with PBS (pH 7.4) containing 0.02% Nonidet P40 and analysed for transgenic b-galactosidase activity indicated by the characteristic blue staining in PBS containing K 3 Fe(CN) 6 (5 mM), K 4 Fe(CN) 6 (5 mM), MgCl 2 (2 mM), 0.02% Nonidet P40, 0.01% sodium deoxycholate and X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside dissolved in N,N-dimethylformamide) at a concentration of 1 mg/ ml. They were stained overnight on a rotary shaker protected from light, subsequently washed three times in PBS and dehydrated in 70% ethanol. Tissue samples were embedded in paraffin, cut into 5 mm sections, counter-stained with neutral red and investigated microscopically.
Detection of vector DNA
Tissue samples from skin, mucous membranes of the oral cavity, liver and gonads of treated mice were investigated for the presence of vector DNA by quantitative real-time PCR, essentially as described previously. 49 The vector AdLAMB3 was detected with the primer pair 5 0 -CAACGGGACTTTCCAAAATG-3 0 (forward) and 5 0 -CTTATCGATACCGTCGACCTC-3 0 (reverse) designed to amplify a 150-bp fragment containing parts of both the CMV promotor and the multiple cloning site. The PCR product was quantified using the dual-labelled fluorogenic probe 5 0 -FAM-ACAACTCCGCCCCATTGACGCA AAT-BHQ-1-3 0 (Biomers.net, Ulm, Germany) binding to the promoter region. Quantification of AAVLAMB3 DNA was performed in an analogous manner using the same forward primer and fluorogenic probe, but the reverse primer 5 0 -ACTCGACGCGTATCTGACG-3 0 binding to the multiple cloning site of AAVLAMB3, which differed from that of AdLAMB3. The reaction mixtures included 50 ng of isolated DNA, the primers at concentrations of 300 nM, the fluorogenic probe (200 nM), dNTPs (200 mM), 0.15 U of Taq DNA polymerase in Thermopol PCR buffer (New England Biolabs) containing Mg 2+ at concentrations of 1.5 and 3.75 mM for AdLAMB3 and AAVLAMB3, respectively. Real-time PCR was performed in parallel to the amplification of 10-fold serial dilutions of the vector DNA (10 8 -10 0 copies) in an iCycler (Bio-Rad, Munich, Germany). Samples were analysed at least in triplicates and standardized to the weight of the tissue used for DNA isolation.
Quantitative RT-PCR
RNA was isolated from the tissues with the NucleoSpin RNA II kit (Macherey Nagel, Dü ren, Germany) and treated with DNAse for 30 min to remove any contaminating genomic or vector DNA. cDNA was synthesised using the RevertAid First Strand cDNA synthesis kit (Fermentas, St Leon-Rot, Germany) according to the manufacturer's protocol, except for the use of an anchored oligo-dT 18 primer. The PCR primers 5 0 -AA GATGTGGTTGGGAACCTG-3 0 (forward) and 5 0 -ATCCG TGTCCAGAAGTCACC-3 0 (reverse) were designed to amplify a fragment of 187 bp of the human but not the murine LAMB3 sequence, spanning exons 19 and 20. Control RT-PCR amplification of a 169 bp fragment of the hypoxanthine-guanine phosphoribosyl transferase housekeeping gene was performed using the primers 5 0 -CTTGCTGGTGAAAAGGACC-3 0 (forward) and 5 0 -GG CTTTGTATTTGGCTTTTCC-3 0 (reverse). The reaction mixtures included 3 ml of the cDNA, SensiMix(dT) (Quantace, Berlin, Germany) with SYBR-Green, added fluorescein (Bio-Rad) and the primers at concentrations of 150 mM each. Real-time PCR was performed in parallel to the amplification of 10-fold serial dilutions of the vector DNA (10 9 -10 1 copies). Melting curves of the PCR products were analysed according to the standard protocols for the iCycler (Bio-Rad), whereas size of the bands and specificity of the reaction were checked by agarose gel electrophoresis. Samples were analysed in triplicates and standardized to the weight of the tissue used for RNA isolation.
Immunofluorescence analysis
Cells infected with AdLAMB3 or AAVLAMB3 in vitro were washed with PBS and fixed in PBS containing 2% paraformaldehyde for 10 min at room temperature. A portion of that was permeabilised with a 0.2% Triton solution (Sigma-Aldrich). After blocking with serum-free blocking buffer (DakoCytomation, Hamburg, Germany), the cells were left to react with the monoclonal antibody K140 detecting the b3 chain of human laminin-5, followed by treatment with a Cy5-labelled anti-mouse secondary antibody (Dianova, Hamburg, Germany).
Frozen 5-mm tissue sections were air-dried for 30 min, fixed with ice-cold methanol, washed twice in PBS, blocked with goat serum and incubated with a rabbit polyclonal antibody recognizing nidogen-1 (diluted 1:500 in PBS) according to the standard protocols. After careful washing, a Cy5-labelled goat anti-rabbit antibody (Dianova, Hamburg, Germany) was applied. To allow the subsequent use of a mouse antibody on mouse tissues, the slides were next treated with blocking reagent and diluent from the MOM kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. The transgenic laminin b3 chain was detected by incubation with the murine monoclonal antibody K140 diluted 1:100 in PBS, followed by a biotinylated anti-mouse secondary antibody and treatment with Texas red-avidin solution. Cell nuclei were stained blue with 4,6,diamidino-2-phenylindole (DAPI) (Roth, Karlsruhe, Germany). Cells and slides were observed under a fluorescence microscope.
Histological analysis
Whole newborn mouse bodies were divided sagittally and fixed in 4% paraformaldehyde for 24 h. After standard dehydration in an automatic tissue-processing machine, the samples were embedded in paraffin. Sagittal 5-mm sections were cut and stained with haematoxylin and eosin. Serial sections throughout the Prenatal LAMB3 gene delivery in mouse model of Herlitz disease C Mühle et al body were examined, and therapeutic effects were evaluated by assessing, semiquantitatively, the extent of tissue separation in skin of the trunk (average percentage of detached epidermis in three sections) and in mucous membranes of the oral cavity.
